ArticleDiscover oncology2025
The effect of microRNA-145 on proliferation and apoptosis of cutaneous squamous cell carcinoma cells.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood-Based miRNA Panels for Timely Detection of Non-Small-Cell Lung Cancer: From Biomarker Discovery to Clinical Translation.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis study aimed to explore the effects of microRNA-145 (miR-145) on the proliferation, cell cycle distribution, and apoptosis of cutaneous squamous cell carcinoma (CSCC) A431 cells.
methodsA431 cells were transfected with miR-145 mimics and negative control microRNA using Lipofectamine 2000. The experiments were divided into three groups: the miR-145 mimics transfection group, the negative control microRNA transfection group, and the blank control group (without any treatment).
resultsThe expression levels of miR-145 were significantly higher in the miR-145 mimics group than in the negative control microRNA group and the blank control group (p < 0.01). The cell proliferation level of the miR-145 mimics group was significantly lower at 24 h, 48 h, and 72 h post-transfection compared to the negative control microRNA group and the blank control group (p < 0.01). The proportion of cells in the G0/G1 phase was significantly higher in the miR-145 mimics group, while the percentage of cells in the S phase was significantly lower (p < 0.01). Additionally, the apoptosis rate in the miR-145 mimics group was significantly higher than that in the negative control microRNA group and the blank control group (p < 0.01). The relative expression levels of Caspase-9 and Caspase-3 were also significantly higher in the miR-145 mimics group (p < 0.01).
conclusionUpregulation of miR-145 expression by miR-145 mimics transfection in CSCC A431 cells significantly inhibited cell proliferation, blocked cell cycle progression at the G0/G1 phase, and promoted apoptosis by increasing the expression of apoptotic proteins Caspase-9 and Caspase-3. These findings suggest that miR-145 may serve as a potential anti-tumor factor in CSCC, highlighting its potential as a therapeutic target for future research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.